Patent Grant
7731985
The present invention relates to substituted 4-aminopyrimidines, to the preparation of such compounds, and to the use of such compounds in the antimicrobial treatment of surfaces, as antimicrobial active substances against gram-positive and gram-negative bacteria, yeasts and fungi and also in the preservation of cosmetics, household products, textiles and plastics and for use in disinfectants.
The present invention relates to the use of 4-aminopyrimidines of formula
groups or by a bivalent heterocyclic radical; NR″R′″-C1-C10 alkyl which is unsubstituted or substituted by a heterocyclic radical or interrupted by one or more —O— or
groups or by a bivalent heterocyclic radical; cyclo-C5-C8alkyl; hydroxy-C1-C20alkyl; phenyl-C1-C3alkyl; a heterocyclic radical; or
C1-C20Alkyl radicals are straight-chain or branched alkyl radicals, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, amyl, isoamyl or tert-amyl, heptyl, octyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl or eicosyl.
C3-C10Cycloalkyl denotes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl. Those radicals may be substituted, for example by one or more identical or different C1-C4alkyl radicals, especially by methyl, and/or by hydroxy. When cycloalkyl radicals are substituted by one or more substituents, they are substituted preferably by one, two or four, especially by one or two, identical or different substituents.
C1-C5Alkoxy radicals are straight-chain or branched radicals such as, for example, methoxy, ethoxy, propoxy, butoxy or pentyloxy.
C6-C10Aryl and heteroaryl radicals may be unsubstituted or may carry one or more, for example one, two, three or four, identical or different substituents, which may be located in any positions. Examples of such substituents are, for example, C1-C4alkyl, halogen, hydroxy, C1-C4alkoxy, trifluoromethyl, cyano, hydroxycarbonyl, C1-C4alkoxycarbonyl, aminocarbonyl, amino, C1-C4alkylamino, di-C1-C4alkylamino and C1-C4alkylcarbonylamino.
Heteroaryl radicals are derived from heterocycles containing one, two, three or four identical or different ring hetero atoms, especially from heterocycles containing one, two or three, more especially one or two, identical or different hetero atoms. The heterocycles may be mono- or poly-cyclic, for example mono-, bi- or tri-cyclic. They are preferably mono- or bi-cyclic, especially monocyclic. The rings preferably contain 5, 6 or 7 ring members. Examples of monocyclic and bicyclic heterocyclic systems from which radicals occurring in the compounds of formula (1) can be derived are, for example, pyrrole, furan, thiophene, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, pyridine, pyridazine, pyrimidine, pyrazine, pyran, thiopyran, 1,4-dioxane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, indole, benzothiophene, benzofuran, pyrrolidine, piperidine, piperazine, morpholine and thiomorpholine.
Unsaturated heterocycles may contain, for example, one, two or three unsaturated double bonds in the ring system. 5-membered rings and 6-membered rings in monocyclic and polycyclic heterocycles may also be, especially, aromatic.
Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
In accordance with the invention, preference is given to the use of compounds of formula (1) wherein
groups or by a bivalent heterocyclic radical;
Very special preference is given to the use of compounds of formula (1) wherein
In accordance with the invention, there are furthermore used compounds of formula (1) wherein
groups;
Among those compounds, preference is given to those wherein
Very special preference is also given to the use of compounds of formula (1) wherein
Among the last-mentioned compounds very special preference is given to the use of those wherein
Also preferably used are compounds of formula (1) wherein, in formula (1a),
Preference is also given to the use of compounds of formula (1) wherein
Special preference is given to the use of compounds of formula
wherein
The Table that follows lists, by way of example, further 4-aminopyrimidines according to the invention:
The 4-aminopyrimidines used in accordance with the invention are prepared by methods known per se (J. Org. Chem.; 1967, 32, 1591). For that purpose, a cyano compound (R1—C≡N) is reacted, in a suitable solvent such as, for example, methanol, ethanol, isopropanol, DMF, tetrahydrofuran etc., with ammonium acetate or ammonium chloride at a temperature of from −10° C. to 100° C. over a period of from 1 hour to 24 hours to form the corresponding amidine compound
The amidine compound is then condensed with an appropriate β-keto ester
using an auxiliary base such as, for example, sodium carbonate, potassium hydroxide, sodium ethanolate, sodium methanolate, potassium tert-butanolate etc., in a suitable solvent such as, for example, methanol, ethanol, butanol, tert-butanol, THF, DMF, acetonitrile, toluene, xylene etc., over a period of from 1 to 24 hours at a temperature of from 40 to 120° C.
The 4-hydroxy-2-pyrimidine compound
thereby obtained is then converted into the corresponding 4-chloro-2-pyrimidine compound
by conventional methods using phosphorus oxychloride.
The substituted 4-aminopyrimidines
are obtained by reacting the 4-chloro-2-pyrimidine compound with a primary or secondary amine (R4R5NH) in a suitable solvent such as, for example, DMF, dioxane, toluene, xylene, ethanol, butanol, and an auxiliary base such as, for example, triethylamine, DIEA, sodium carbonate, potassium hydroxide etc., or using an excess of amine at from 40 to 130° C. over a period of from 1 to 24 hours.
The entire reaction proceeds according to the following scheme:
R1, R2, R3, R4 and R5 being as defined for formula (1).
Preparation of the compounds of formula (2) is carried out by reacting an excess of from 2 to 10 equivalents of the diamine compound H2N(CH2)nX(CH2)mNH2 in, for example, DMF, dichloromethane, THF or dioxane with trityl chloride polystyrene resin at a temperature of from 10 to 50° C. over a period of from 0.5 to 24 hours. From 2 to 10 equivalents of the appropriately substituted 4,6-dichloropyrimidines
are then reacted, in a suitable solvent such as, for example, dichloromethane, DMF, THF or toluene, with the polymer-bound diamines at from 10 to 120° C. over a period of from 2 to 48 hours. The 4-chloropyrimidines are reacted with from 2 to 10 equivalents of various boronic acids, from 1 to 10% of palladium catalyst and from 2 to 10 equivalents of auxiliary base such as, for example, CaCO3 and NaCO3, in, for example, THF, DMF or dioxane. After washing the resin to remove the excess, the target compounds are split off using from 1 to 30% trifluoroacetic acid (TFA) in dichloromethane (DCM) at 25° C. over a period of from 1 to 5 hours. For the purpose of further purification, the substances are freeze-dried from tBuOH/water 4:1 with from 1 to 10% HOAc and once from tBuOH/water 4:1.
The entire reaction proceeds according to the following scheme:
R1, R2, R3, X, m and n being as defined for formula (2).
Some of the 4-aminopyrimidines used in accordance with the invention are known from the literature and some are novel compounds. The invention relates also to those novel compounds.
The novel compounds correspond to formula
groups or by a bivalent heterocyclic radical; NR″R′″-C1-C20alkyl which is unsubstituted or substituted by a heterocyclic radical or interrupted by one or more —O— or
groups or by a bivalent heterocyclic radical; cyclo-C5-C8alkyl; hydroxy-C1-C20alkyl; phenyl-C1-C3alkyl; a heterocyclic radical; or
The 4-aminopyrimidines used in accordance with the invention exhibit pronounced antimicrobial action, especially against pathogenic gram-positive and gram-negative bacteria and against bacteria of the skin flora, and also against yeasts and moulds. They are accordingly suitable especially for disinfection, deodorisation, and for general and antimicrobial treatment of the skin and mucosa and of integumentary appendages (hair), more especially for the disinfection of hands and wounds.
They are accordingly suitable as antimicrobial active substances and preservatives in personal care preparations such as, for example, shampoos, bath additives, haircare preparations, liquid and solid soaps (based on synthetic surfactants and salts of saturated and/or unsaturated fatty acids), lotions and creams, deodorants, other aqueous or alcoholic solutions, e.g. cleansing solutions for the skin, moist cleaning cloths, oils or powders.
The invention accordingly relates also to a personal care preparation comprising at least one compound of formula (1) and cosmetically tolerable carriers or adjuvants.
The personal care preparation according to the invention contains from 0.01 to 15% by weight, preferably from 0.1 to 10% by weight, based on the total weight of the composition, of a compound of formula (1), and cosmetically tolerable adjuvants.
Depending upon the form of the personal care preparation, it comprises, in addition to the 4-aminopyrimidine of formula (1), further constituents such as, for example, sequestering agents, colorants, perfume oils, thickeners or solidifiers (consistency regulators), emollients, UV-absorbers, skin protective agents, antioxidants, additives that improve the mechanical properties, such as dicarboxylic acids and/or aluminium, zinc, calcium or magnesium salts of C14-C22fatty acids, and, optionally, preservatives.
The personal care preparation according to the invention may be in the form of a water-in-oil or oil-in-water emulsion, an alcoholic or alcohol-containing formulation, a vesicular dispersion of an ionic or non-ionic amphiphilic lipid, a gel, a solid stick or an aerosol formulation.
As a water-in-oil or oil-in-water emulsion, the cosmetically tolerable adjuvant contains preferably from 5 to 50% of an oil phase, from 5 to 20% of an emulsifier and from 30 to 90% water. The oil phase may comprise any oil suitable for cosmetic formulations such as, for example, one or more hydrocarbon oils, a wax, a natural oil, a silicone oil, a fatty acid ester or a fatty alcohol. Preferred mono- or poly-ols are ethanol, isopropanol, propylene glycol, hexylene glycol, glycerol and sorbitol.
Cosmetic formulations according to the invention are used in various fields. There come into consideration, for example, especially the following preparations:
An antimicrobial soap has, for example, the following composition:
A shampoo has, for example, the following composition:
A deodorant has, for example, the following composition:
The invention relates also to an oral composition containing from 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1), and orally tolerable adjuvants.
Example of an oral composition:
The oral composition according to the invention may be, for example, in the form of a gel, a paste, a cream or an aqueous preparation (mouthwash).
The oral composition according to the invention may also comprise compounds that release fluoride ions which are effective against the formation of caries, for example inorganic fluoride salts, e.g. sodium, potassium, ammonium or calcium fluoride, or organic fluoride salts, e.g. amine fluorides, which are known under the trade name Olafluor.
The 4-aminopyrimidines of formula (1) used in accordance with the invention are also suitable for treating, especially preserving, textile fibre materials. Such materials are undyed and dyed or printed fibre materials, for example of silk, wool, polyamide or polyurethanes, and especially cellulosic fibre materials of all kinds. Such fibre materials are, for example, natural cellulose fibres, such as cotton, linen, jute and hemp, as well as cellulose and regenerated cellulose. Preferred suitable textile fibre materials are made of cotton.
The 4-aminopyrimidines according to the invention are suitable also for treating, especially imparting antimicrobial properties to or preserving, plastics such as, for example, polyethylene, polypropylene, polyurethane, polyester, polyamide, polycarbonate, latex etc. Fields of use therefor are, for example, floor coverings, plastics coatings, plastics containers and packaging materials; kitchen and bathroom utensils (e.g. brushes, shower curtains, sponges, bathmats), latex, filter materials (air and water filters), plastics articles used in the field of medicine such as, for example, dressing materials, syringes, catheters etc., so-called “medical devices”, gloves and mattresses.
Paper, for example papers used for hygiene purposes, may also be provided with antimicrobial properties using the 4-aminopyrimidines according to the invention.
It is also possible for nonwovens such as, for example, nappies/diapers, sanitary towels, panty liners, and cloths for hygiene and household uses, to be provided with antimicrobial properties in accordance with the invention.
The 4-aminopyrimidines of formula (1) are also used in washing and cleaning formulations such as, for example, liquid or powder washing agents or softeners.
The 4-aminopyrimidines of formula (1) can also be used especially in household and general-purpose cleaners for cleaning and disinfecting hard surfaces.
A cleaning preparation has, for example, the following composition:
In addition to preserving cosmetic and household products, the preservation of technical products, the provision of technical products with antimicrobial properties and use as a biocide in technical processes are also possible, for example in paper treatment, especially in paper treatment liquors, printing thickeners of starch or cellulose derivatives, surface-coatings and paints.
The 4-aminopyrimidines of formula (1) are also suitable for the antimicrobial treatment of wood and for the antimicrobial treatment of leather, the preserving of leather and the provision of leather with antimicrobial properties.
The compounds according to the invention are also suitable for the protection of cosmetic products and household products from microbial damage.
The following Examples illustrate, but do not limit, the present invention.
2.2 g of benzamidine hydrochloride (14.05 mmol) are reacted, in 10 ml of absolute EtOH, with 5.43 ml (14.05 mmol) of 20% sodium ethanolate solution and then condensed with 1.66 g of methyl acetoacetate (14.29 mmol) for 4 hours at 90° C.
The crude product is concentrated by evaporation and taken up in 30 ml of toluene.
4.31 g of phosphorus oxychloride (28.1 mmol) are added and the reaction mixture is heated at 120° C. for 3 hours. After cooling to 20° C., the excess is neutralised with sodium hydroxide solution, and the mixture is diluted with ethyl acetate and then washed with water and saturated sodium chloride solution.
The product solution is dried over sodium sulfate and concentrated by evaporation.
2.2 g of 4-chloro-6-methyl-2-phenylpyrimidine (77.7% of theory) are obtained.
20.5 mg of 4-chloro-6-methyl-2-phenylpyrimidine (0.1 mmol) are heated with 3 equivalents of monoamines (0.3 mmol) in 0.5 ml of absolute dioxane at 100° C. for 20 hours. After cooling, the products are concentrated in vacuo, taken up in t-BuOH/water 4/1 and freeze-dried. The end products are analysed by LC-MS.
In each case, 50 mg of resin (1.29 mmol/g) are shaken in 1 ml of DMF with 94 mg of N,N-bis(3-aminopropyl)methylamine (0.645 mmol) at 25° C. for 3 hours. The resin is filtered off and washed with DCM, MeOH, THF, MeOH and DCM and dried in vacuo.
The resin is shaken in 1 ml of DMF with 0.194 g of 4,6-dichloro-2,5-diphenylpyrimidine (0.645 mmol) and 90 μl of triethylamine (0.645 mmol) at 25° C. for 3 hours.
The resin is filtered off and washed with DCM, MeOH, THF, MeOH, DCM and MeOH and dried in vacuo.
The resin is heated with 126.1 g of caesium carbonate (6 eq., 0.387 mmol) and 300 μL of a toluene solution of 0.1 eq. of a palladium catalyst (WO 01/16057) at 95° C. for 15 minutes. After adding 3 eq. of a boronic acid, dissolved in 700 μl of toluene solution, the mixture is heated at 90° C. for 1 hour.
After cooling, the resin is filtered off and washed with DMF, MeOH, THF, MeOH and DCM and dried in vacuo.
The products are split off using 1.5 ml of a 5% TFA/DCM solution at room temperature for 3 hours. The resin is then washed with 1 ml of DCM and 1 ml of MeOH, and the combined solutions are concentrated to dryness by evaporation. The end products are analysed by LC-MS.
2.5 g of 4-methyl-benzamidine hydrochloride (14.65 mmol) are reacted in 10 ml of absolute EtOH with 5.66 ml of a 20% solution of sodium ethanolate (14.65 mmol) and then condensed with 1.73 g of methyl acetoacetate (14.88 mmol) at 90° C. for 4 hours. The crude product is concentrated by evaporation and taken up in 30 ml of toluene. 6.74 g of phosphorus oxychloride (44.0 mmol) are added and the reaction mixture is heated at 120° C. for 3 hours. After cooling to 20° C., the excess is neutralised with sodium hydroxide solution, and the mixture is diluted with ethyl acetate, washed with saturated sodium hydrogen carbonate solution and then with water. The product solution is concentrated by evaporation and separated by column chromatography (hexane/EE: 5/1). 2.1 g of 4-chloro-6-methyl-2-tolylpyrimidine (66.5% of theory) are obtained.
NMR: 1H (ppm in DMSO): 2.4, s, 3H; 2.55, s, 3H; 7.3, d, 2H; 7.5, s, 1H; 8.25, d, 2H
21.9 mg of 4-chloro-6-methyl-2-(4-methyl)-phenylpyrimidine (0.1 mmol) are heated with 3 eq. of monoamines (0.3 mmol) in 0.5 ml of absolute dioxane at 100° C. for 20 hours. After cooling, the products are concentrated in vacuo, taken up in t-BuOH/water 4/1 and freeze-dried. The end products are analysed by LC-MS.
1.36 g of 4-chloro-6-methyl-2-(4-methyl)-phenylpyrimidine (6.23 mmol) are heated with 886 mg of octylamine (6.85 mmol) and 2.58 g of potassium carbonate (18.68 mmol) in 10 g of dioxane at 100° C. for 48 hours. After cooling, the product is taken up in 100 ml of ethyl acetate and washed with sodium hydroxide solution 0.5 mol/l, saturated sodium hydrogen carbonate solution and water. The product is concentrated in vacuo, taken up in t-BuOH/water 4/1 and freeze-dried.
1.92 g of 4-chloro-6-methyl-2-(4-methyl)-phenylpyrimidine (6.15 mmol, 98.7% of theory) are obtained.
The end product is analysed by NMR, GC-MS and GC.
NMR 1H (ppm in DMSO): 0.9, t, 3H; 1.25, m, 12H; 1.55, m, 2H; 2.25, s, 3H; 2.3, s, 3H; 6.4, s, 1H; 7.1, m, 1H; 7.2, d, 2H; 8.2, d, 2H; (m/z=311);
GC: 95% purity
76.1 g of 2-isopropyl-6-methyl-4-pyrimidinol [2814-20-2] (500 mmol) are dissolved in 300 ml of toluene at 90° C. 80.5 g of phosphorus oxychloride (525 mmol) are added dropwise thereto at from 90 to 103° C., and the reaction mixture is heated at 110° C. for 2 hours. After cooling to 20° C., the reaction mixture is adjusted to pH 8 using 4M sodium hydroxide solution, with cooling. The aqueous phase is separated off and extracted with 100 ml of toluene. The combined organic phases are washed three times with 100 ml of water each time and dried at RT under 2 mbar. 89.7 g (105%; contains toluene) are obtained.
79.2 g of 4-chloro-2-isopropyl-6-methylpyrimidine (464.1 mmol) are heated in 100 ml of dioxane at 100° C. A heated solution of 189.3 g of dodecylamine (1021 mmol, 2.2 eq) in 30 ml of dioxane is added dropwise thereto over the course of 2 hours, and the reaction mixture is further heated for 2 hours at 100° C. and for 9 hours at 109° C. After cooling, 400 ml of ethyl acetate and 150 ml of 4M sodium hydroxide solution (600 mmol) are added thereto and the mixture is stirred at 50° C. for 10 minutes. The lower, aqueous phase is discarded, the organic phase is washed with 300 ml of water, and 10 ml of saturated NaCl solution are added thereto. The organic phase is separated off and concentrated, and the excess dodecylamine is distilled in vacuo up to a bath temperature of 160° C. 136.1 g (91.8%); GC purity: 98%
NMR 1H (ppm in CDCl3): 0.7, t, 3H; 1.1, m, 24H; 1.4, m, 2H; 2.15, s, 3H; 2.75, Q, 1H; 3.05, m, 2H; 4.9, s, 1H; 5.8, s, 1H
Nutrient Medium:
Casein/soymeal peptone broth for preparation of pre-cultures of test bacteria and yeast
Examples of Test Organisms:
Bacteria:
Procedure:
The test substances are pre-dissolved in dimethyl sulfoxide (DMSO) and tested in a dilution series of 1:2.
Bacteria and yeast are cultured overnight in CASO broth.
All the test organism suspensions are adjusted to an organism count of 1-5×106 CFU/ml using 85% sodium chloride solution.
The test substances are pre-pipetted into microtitre plates in amounts of 8 μl per well.
The pre-adjusted organism suspensions are diluted 1:100 in CASO broth and are added in amounts of 192 μl per well to the test substances.
The test batches are incubated for 48 hours at 37° C.
The incubation, the growth is determined on the basis of the turbidity of the test batches (optical density) at 620 nm in a microplate reader.
The minimum inhibitory concentration (MIC value) is the concentration of substance at which (compared to the growth of the control) an appreciable inhibition of growth (≦20% growth) of the test organisms is observed.
Three microtitre plates are used for each test organism and substance concentration. All the substances are tested in duplicate.
The microbiological test results are compiled in Table 2:
Test Principle:
0.3 ml of each dilution step is mixed with 15 ml of nutrient medium while the latter is still liquid. After the nutrient medium has solidified, 10 μl of each of the following organism dilutions of the test strains in 0.85% NaCl solution are spotted onto the agar medium:
Microorganisms Used:
Staphylococcus aureus ATCC 6538
Staphylococcus aureus
Staphylococcus epidermidis
Corynebacterium xerosis*
C. minutissimum ATCC 23348
Propionibacterium acnes (*)
Escherichia coli NCTC 8196
Escherichia coli ATCC 10536
Proteus vulgaris ATCC 6896
Klebsiella pneumoniae
Salmonella choleraesuis ATCC 9184
Pseudomonas aeruginosa
Candida albicans ATCC 10231
Aspergillus niger ATCC 6275
The plates are incubated at 37° C. for 24 hours (A. niger at 28° C. for 3 days) and then the highest dilution (lowest concentration) of the test substance at which growth is just no longer discernible (corresponds to the MIC) is determined. The results are shown in Table 3.
Staphylococcus aureus ATCC 6538
Staphylococcus aureus ATCC 9144
Staphylococcus epidermidis ATCC 12228
Corynebacterium xerosis* ATCC 373
C. minutissimum ATCC 23348
Propionibacterium acnes (*) ATCC 6919
Escherichia coli NCTC 8196
Escherichia coli ATCC 10536
Proteus vulgaris ATCC 6896
Klebsiella pneumoniae ATCC 4352
Salmonella choleraesuis ATCC 9184
Pseudomonas aeruginosa ATCC 15442
Candida albicans ATCC 10231
Aspergillus niger ATCC 6275
Test Method:
Nutrient Medium:
Examples of Test Organisms:
Procedure:
The test substances are dissolved in dimethyl sulfoxide (DMSO) and tested in a concentration of 120 μg/ml.
Bacteria are incubated overnight in CASO broth and adjusted to an organism count of 1-5×105 CFU/ml using 0.85% sodium chloride solution.
The test substances are pre-pipetted into microtitre plates in amounts of 8 μl per well.
The adjusted test organism suspensions are added in amounts of 192 μl per well to the test substances and mixed. After defined contact times, the test batches are mixed, an aliquot is withdrawn and diluted in several steps in a dilution series of 1:10 in a suitable inactivation medium.
The test plates are incubated for 24 hours at 37° C. After incubation, the growth is determined on the basis of the turbidity of the test batches (optical density) at 620 nm in a microplate reader.
On the basis of the number of steps in the dilution series that exhibit growth, the reduction in the test organism concentration is determined in powers of ten (log value).
One microtitre plate is used for each test organism.
All the substances are tested in duplicate.
The results (log reduction) are shown in Table 4:
S. aureus
S. aureus
E. coli
E. coli
A. viscosus
A. viscosus
Nutrient medium and test procedure correspond to Example 10.
As test organisms there are used:
Microbiological test results are compiled In Table 5:
| Number | Date | Country | Kind |
|---|---|---|---|
| 02405201 | Mar 2002 | EP | regional |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP03/02438 | 3/10/2003 | WO | 00 | 9/13/2004 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO03/077656 | 9/25/2003 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4435402 | Tsuji et al. | Mar 1984 | A |
| 5250530 | Giencke et al. | Oct 1993 | A |
| 5668140 | Schaper et al. | Sep 1997 | A |
| 6207668 | Braun et al. | Mar 2001 | B1 |
| 7015228 | Haap et al. | Mar 2006 | B2 |
| Number | Date | Country |
|---|---|---|
| 2 340 405 | Feb 2000 | CA |
| 2340405 | Feb 2000 | CA |
| 0323757 | Jul 1989 | EP |
| 0407899 | Jan 1991 | EP |
| 0424125 | Apr 1991 | EP |
| 0519211 | Dec 1992 | EP |
| 1 254 903 | Nov 2002 | EP |
| 9507278 | Mar 1995 | WO |
| WO 9507278 | Mar 1995 | WO |
| 9961439 | Dec 1999 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20050143387 A1 | Jun 2005 | US |
